Fox Chase patients may be eligible to receive third COVID-19 vaccine dose – Read More


Matthew R. Zibelman, MD

Matthew Zibelman, MD

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111


Assistant Professor, Department of Hematology/Oncology

Research Program

Treatment Philosophy

I am a medical oncologist specializing in the treatment of genitourinary cancers.  As a medical oncologist, I work with patients at all phases of malignant disease, which allows me the opportunity to join patients and families on a journey that can be at times both exhilarating and exhausting.  I understand that the patient-oncologist relationship is a unique partnership and one that I take seriously.  The journey of cancer provides access to moments in life that can be emotionally challenging for all parties, and I view my role as one ultimately about providing information and guidance to help navigate the path in the way best suited to each patient.

I find genitourinary oncology to be a particularly satisfying and exciting field within medical oncology.  It includes a diverse group of patients and a variety of different disease with their own unique opportunities and challenges.  It is an area involved in a great deal of research, which has afforded new treatment options for patients, and allows me to be involved in helping patients live longer, live better, and in some instances, even help cure them of their disease.    

Fortunately, at Fox Chase Cancer Center, our faculty and staff are dedicated and united towards one goal – optimally treating patients with cancer.  I completed my oncology training at Fox Chase and was fortunate to be able to continue as an attending physician at this world-class institution.  As part of Fox Chase, our patients have access to the cutting edge of clinical oncology, including the ability to have access to exciting new drugs as part of clinical trials.  Medical oncology is a rapidly evolving world, with new treatments and possibilities continually being made available to improve patient outcomes, and Fox Chase strives to remain at the forefront of those changes. 

Education and Training

Educational Background

  • Fellow, Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Resident, Internal Medicine, University of Illinois at Chicago Medical Center, Chicago, IL
  • MD, Lewis Katz School of Medicine, Temple University, Philadelphia, PA


  • Society for Immunotherapy of Cancer
  • American Society of Clinical Oncology
  • American Society of Hematology
Patient Stories

Tom Maguire

Bladder Cancer

Tom Maguire

Bladder Cancer

"In 2018 I was diagnosed with muscle invasive bladder cancer, which seemed like it would end my diving, but also provided me a new way to give back."

John Mullarkey, Jr.

Prostate Cancer

John Mullarkey, Jr.

Prostate Cancer

I have always been proactive about my health and started having annual prostate exams when I turned 50 in 2007. My first report was great and showed that my PSA level was undetectable.

Research Profile

Research Program

Research Interests

  • Genitourinary Oncology
  • Immune Related Adverse Events
  • Immunotherapy

Selected Publications

Zibelman M, Plimack ER. Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm. Oncology. 2016 Feb; 30(2): 160-2. PubMed

Zibelman M, Pollak N, Olszanski AJ. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer. 2016 Feb 16;4:8. PubMed

Zibelman M, Wong YN, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.  Investigational New Drugs. 2015 Oct; 33 (5): 1040-7.  PubMed

Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM . A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report from the Website. Clinical Genitourinary Cancer. 2015 Apr; 13(2):142-9. PubMed

Ghatalia P, Koenigsberg R, Pisarcik D, Handorf EA, Plimack ER, Geynisman DM, Zibelman M. The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the Website. Kidney Cancer. 2017. December. 1(2):151-159

Zibelman M, Plimack ER. Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake. Immunotherapy. 2018. Mar 1; 10(6): 423-425

Zibelman M, Plimack ER. Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old? Annals of Translational Medicine. 2019. July; 7(Suppl 3): S95

Cole S, Zibelman M, Bertino E, Yucebay F, Reynolds K. Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions. American Society of Clinical Oncology Educational Book 39 (May 17, 2019) 96-104

Dawson NA, Zibelman M, Lindsay T, Feldman RA, Saul M, Gatalica Z, Korn WM, and Heath EI. An emerging landscape for canonical and actionable molecular alterations in primary and metastatic prostate cancer. Molecular Cancer Therapeutics. 2020.19:1373–82. Published on-line March 27, 2020

Anari F, Ramamurthy C, Zibelman M. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer. Future Oncology. 2018 Jun; 14(14): 1409-142

Additional Publications




Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.


4.9 / 5.0


  • 4.9
  • 4.9
  • 4.9
  • 4.9
  • 4.8


  • 5.0
    June 28, 2021
    Always willing to carefully consider any concerns I may bring up!
  • No Star Ratings Available June 17, 2021
    Dr. Zibelman was Exceptional is delivery of the information I needed.
  • 5.0
    May 18, 2021
    I have been in the medical field as a nurse mgr. for many [...] & have had Dr. Zibelman care for me for approx. 6 yrs. with breast cancer and I can only say he is the most caring, understanding and sensitive physician I have ever had - I would only hope other physicians could and would follow in his footsteps. As far as his medical knowledge he never lets a stone unturned.
  • 5.0
    April 20, 2021
    All good!
  • 5.0
    April 15, 2021
  • 5.0
    March 19, 2021
    I have always found that Fox Chase Cancer center -- and PARTICULARLY Dr. Zibelman and his excellent staff -- are simply the best providers around. Dr. Zibelman (and Nurse [...] and the other on-site nurses) are just over the top with their care and attention to me and my complicated needs. I'm very fortunate to be connected with them.
  • 5.0
    March 19, 2021
    Dr. Zibelman's team is tops.
  • No Star Ratings Available March 03, 2021
    He is very concerned about my health!
  • 5.0
    January 24, 2021
    I've changed doctors quite a lot since being diagnosed with prostate cancer. I like Dr. Z. the best.
  • No Star Ratings Available January 20, 2021
    Dr Ziebelman was thorough and patient in his manner and info gathering. Good listener, clearly competent. Kind and calm.
  • No Star Ratings Available January 19, 2021
    Dr. Zibelman has given me excellent care.
  • 5.0
    January 02, 2021
  • No Star Ratings Available December 02, 2020
    Fantastic dr. and hospital.
  • 5.0
    November 28, 2020
  • 5.0
    November 26, 2020
  • 5.0
    November 18, 2020
    Dr Zibbleman is very concerned about my health!
  • 5.0
    October 30, 2020
    Experience was exceptional all my visits have been good. No complaints what so ever
  • 5.0
    October 22, 2020
    Dr. Zibelman has LITERALLY saved my life, and he continues to work with me.
  • 5.0
    October 16, 2020
    all good
  • 5.0
    October 03, 2020
    very satisfied

Connect with Fox Chase